Atea Pharmaceuticals (NASDAQ:AVIR) & ZyVersa Therapeutics (NASDAQ:ZVSA) Critical Contrast

Atea Pharmaceuticals (NASDAQ:AVIR) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares Atea Pharmaceuticals and ZyVersa Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35 million	($1.94)	-2.80
ZyVersa Therapeutics	N/A	N/A	-$9.41 million	($1.34)	-0.14

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Atea Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Profitability

This table compares Atea Pharmaceuticals and ZyVersa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-46.34%	-42.52%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Analyst Ratings

This is a summary of recent ratings for Atea Pharmaceuticals and ZyVersa Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1	0	0	1	2.50
ZyVersa Therapeutics	0	0	0	0	0.00

Summary

Atea Pharmaceuticals beats ZyVersa Therapeutics on 6 of the 10 factors compared between the two stocks.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.